FDA-Approved Molecular Diagnostic Reagent Supply for Infectious Disease Testing

The contract entails the supply of FDA-cleared molecular diagnostic test cartridges and reagents for syndromic infectious disease panels, covering key pathogens including SARS-CoV-2, influenza, RSV, C. difficile, Strep A, MRSA, MTB/Rif, and a gastrointestinal panel. All products must be fully compatible with analyzers owned by the Department of Veterans Affairs and maintained within a strict temperature range of 2–28°C during shipping and storage to ensure stability and diagnostic accuracy. The equipment and reagents are intended for use in VA healthcare settings to support rapid, reliable infectious disease testing across multiple clinical scenarios. This subcontract is managed by the 260-NETWORK Contract Office 20 under the Department of Veterans Affairs, with performance centered in Seattle, Washington, at the zip code 98108. The solicitation was posted on July 30, 2026, with a response deadline of August 6, 2027, providing vendors a nearly 13-month window to submit proposals. The North American Industry Classification System code 325412 confirms the focus on pharmaceutical and medicinal chemical manufacturing, underscoring the technical and regulatory rigor required for compliance with federal diagnostic standards. The contract will support the VA’s mission to deliver timely, evidence-based infectious disease diagnostics to veterans through established laboratory infrastructure.